- Home
- ITRG vs ACRS Comparison
ITRG vs ACRS Comparison
Compare ITRG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- ACRS
- Stock Information
- Founded
- ITRG 1997
- ACRS 2012
- Country
- ITRG Canada
- ACRS United States
- Employees
- ITRG N/A
- ACRS N/A
- Industry
- ITRG Precious Metals
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- ACRS Health Care
- Exchange
- ITRG Nasdaq
- ACRS Nasdaq
- Market Cap
- ITRG N/A
- ACRS 170.9M
- IPO Year
- ITRG N/A
- ACRS 2015
- Fundamental
- Price
- ITRG $1.24
- ACRS $1.53
- Analyst Decision
- ITRG Strong Buy
- ACRS Strong Buy
- Analyst Count
- ITRG 1
- ACRS 7
- Target Price
- ITRG $2.75
- ACRS $11.67
- AVG Volume (30 Days)
- ITRG 488.2K
- ACRS 1.2M
- Earning Date
- ITRG 03-26-2025
- ACRS 05-06-2025
- Dividend Yield
- ITRG N/A
- ACRS N/A
- EPS Growth
- ITRG N/A
- ACRS N/A
- EPS
- ITRG N/A
- ACRS N/A
- Revenue
- ITRG $30,350,000.00
- ACRS $18,720,000.00
- Revenue This Year
- ITRG $490.21
- ACRS N/A
- Revenue Next Year
- ITRG $37.03
- ACRS N/A
- P/E Ratio
- ITRG N/A
- ACRS N/A
- Revenue Growth
- ITRG N/A
- ACRS N/A
- 52 Week Low
- ITRG $0.71
- ACRS $0.95
- 52 Week High
- ITRG $1.38
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- ITRG 53.74
- ACRS 28.64
- Support Level
- ITRG $1.18
- ACRS $1.57
- Resistance Level
- ITRG $1.38
- ACRS $1.78
- Average True Range (ATR)
- ITRG 0.09
- ACRS 0.10
- MACD
- ITRG -0.00
- ACRS 0.02
- Stochastic Oscillator
- ITRG 53.33
- ACRS 17.74
Stock Price Comparison Chart: ITRG vs ACRS
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.